Objectives: To compare the clinical outcomes of adolescents and young adults with anorexia nervosa (AN) comorbid with broad autism spectrum disorder (ASD) or ASD traits.
| I N TR ODU C TI ON
Neurodevelopmental disorders have been associated with eating disorders (ED), with attention-deficit/hyperactivity disorder linked to bulimia nervosa (BN) and binge-eating disorder (Nazar et al., 2016) , and autism spectrum disorders (ASDs) to anorexia nervosa (AN) Tchanturia et al., 2013) . There has been interest in the impact these might have upon treatment and prognosis (Westwood & Tchanturia, 2017) .
In a Swedish cohort of AN adolescents, 32% had ASD traits at some time over the course of 18 years follow-up and this sub-group had a poorer long term prognosis (Anckarsäter et al., 2012) , with particular problems in mental and social functioning (Nielsen et al., 2015) . In a series of AN cases referred to a specialized child and adolescent service, 6.9% had broad ASD traits (using the autism-spectrum quotient) and this sub-group were more likely to progress to more intensive levels of care (day or inpatient) (Stewart, McEwen, Konstantellou, Eisler, & Simic, 2017) . In line with these findings, we have previously reported that 19% of AN adolescents presenting for treatment had ASD traits with 4% receiving a probable/possible ASD diagnosis (Rhind et al., 2014) . These findings suggest that people with AN and associated ASD traits may have a less favorable prognosis.
We therefore aimed to examine the 12 months outcomes of patients who had ASD traits and those with a probable/possible ASD diagnosis in a sample of individuals with AN participating in a randomized controlled trial.
| M E TH OD
The present report is a secondary data analysis from the Experienced Carers Helping Others (ECHO) trial. This trial aimed to assess the benefits of a carer intervention added to usual treatment, where they received materials and telephone coaching to better cope with their offspring's ED.
Participants were aged between 13 and 21 and consisted of 149 adolescents with AN or Atypical AN, among which, 15.4% had ASD traits and 4% received a possible/probable ASD diagnosis. Some baseline features have been described previously (Rhind et al., 2014) as well as details regarding the original trial (Hibbs et al., 2015) .
| A SSE SSM EN T M E A SURE S
Details regarding measures can be found in the Supporting Information and are summarized below:
The developmental and well-being assessment (DAWBA) (Goodman, Ford, Richards, Gatward, & Meltzer, 2000) . Both parent and patients completed the ED and ASD modules for this computerized diagnostic instrument and trained psychiatrists confirmed the psychiatric diagnosis afterwards (DSM-IV [American Psychiatric Association, 2000] and ICD-10 [World Health Organization, 1993] ).
Strengths and difficulties questionnaire (SDQ) (Goodman & Scott, 1999 ). An instrument with five sub-scales (peer problems, prosocial difficulties, hyperactivity, emotional problems, and conduct problems), completed both by parent and patients at baseline and 12 months.
Social aptitude scale (SAS) (Liddle, Batty, & Goodman, 2009 ). Parents report retrospectively on their child's social development comparing their child's abilities to those of their peers, completed at baseline only.
The short evaluation of eating disorders (SEED) (Bauer, Winn, Schmidt, & Kordy, 2005) . A six-item measure of ED symptom severity.
The outcomes include a three items severity score for AN (ANTSI) and three items for BN (BNTSI). The score from each item can range from 0 to 3 (0 5 symptom not present; 3 5 symptom is extreme).
The depression, stress and anxiety scale (DASS-21) (Henry & Crawford, 2005) . A shortened version of the DASS with good internal consistency on each of the sub-scales. Mann-Whitney U tests compared differences between sub-groups where the data was non-parametrically distributed. Chi-square tests were performed for comparing proportions and Spearman correlations for non-parametric associations.
| RE S U L TS
The baseline sociodemographic characteristics are presented in Table 1 and the clinical characteristics are presented in Table 2 . Regarding ECHO treatment allocation, there were no significant differences between AN only and broad ASD traits groups (X 2 5 .077; p 5 .782).
Participants with broad ASD traits had had more general inpatient and day-patient days (U 5 1,077.0, z 5 2.433, p 5 .015) and had been more frequently admitted to an ED specialist inpatient treatment (18.2% vs.
5%; (X 2 5 6.62; p 5 .02). Furthermore, the ASD group presented with more antipsychotic use (X 2 5 11.74; p < .001) prior to presentation.
Baseline SAS scores were significantly and inversely correlated with baseline antipsychotic use in the total sample (rho 5 2.21; p 5 .017). At baseline, ED symptoms were similar between groups but the group with broad ASD traits had higher parental (p < .0001) and self-reported (U 5 795.5, z 5 22.16, p 5 .03) total general difficulties on the SDQ.
There was no significant difference (X 2 5 .588; p 5 .44) between the proportion of participants who completed the 12 month follow-up in the AN only (80.1%) and the broad ASD traits group (86.95%). Both
groups had similar increases in BMI and weight for height from baseline to 12 months, as well as similar reductions in ED symptoms. After 12 months, there were no differences between the groups in medication use (X 2 5 2.44; p 5 .111) ( Table 1) .
Both groups had decreases in general difficulties (SDQ) over time. Table 3 for AN only versus Broad ASD traits group, and SDQ data from the ASD subset is presented in a different version of this table on the Supporting Information.
5.1 | The "ASD probable/possible diagnosis" subgroup
The social difficulties of the six participants (five possible, one definite)
with an ASD diagnosis improved over time (d 5 2.02; p 5 .03) but, as expected, remained higher than in the other group of patients. Other domains of difficulties also improved (Table 2) .
We One patient experienced continuing social and mood problems and another severe OCD. The remaining two were not in treatment and were presumed to be well.
| D ISC USSION
The aim of this study was to examine the clinical course of young people with AN who also had ASD traits (broad and narrow/diagnostic).
The ASD traits group had a greater use of intensive treatment (in/daypatient) and medication use before presentation to the specialist clinic and more general difficulties (SDQ), both at baseline and after receiving specialist treatment. However, eating disorder symptoms (BMI, weight for height and SEED) in the broad and narrow/diagnostic groups did not differ from the comparison group both at baseline and at 12 months. The majority of the narrow/diagnostic group continued to have contact with mental health services 2 years after presentation, two of whom had a persistent eating disorder. A poorer prognosis in the ASD group appears to relate to the more severe general comorbidity than to the eating disorder outcomes alone.
The 15.4% (23/149) prevalence of SAS scores below cut-off (ASD traits group) in this sample is the same as that found in a clinical cohort of AN and EDNOS cases (Stewart et al., 2017) . However, the computer generated probability of ASD diagnosis from the DAWBA in the clinical cohort (Stewart et al., 2017) did not differ from community norms, while in our sample, a trained psychiatrist reviewed the DAWBA and we found one probable and five possible cases (Rhind et al., 2014) .
There were differences in the clinical specifiers between these studies.
The clinical cohort (Stewart et al., 2017) included people with an age range of 9-18 (mean 5 14.6), whereas the current study included people from age 13-21 years (mean 5 17). Previous studies suggest that the prevalence of ASD traits varies according to the age/duration of illness of the sample included. For example, in a recent meta-analysis lower levels of ASD traits were reported in children/adolescents than in adult samples (Westwood et al., 2016) . Also, the number of cases who met diagnostic criteria for ASD was higher in inpatients with a more severe form of illness (Wentz et al., 2005) .
In this study, we found that although ED related symptoms and physical recovery did not differ between groups, there was a greater severity of residual general comorbidity in the group with ASD. The group with ASD traits had had more intensive treatment at baseline and a large proportion of those with probable/possible diagnosis .5 (6 .6) N5107
.48 (p < .001)
. .08** (no effect) AN 1 broad ASD 3 (13.6%) | 177 remained in treatment. In the Swedish cohort followed up over 30 years, participants with ASD traits were found to have a poorer global outcome (using Morgan and Russell scales) (Nielsen et al., 2015) . Inpatients with ASD traits and/or diagnosis also didn't improve as much as their non-ASD counterparts from group Cognitive Remediation Therapy (Tchanturia, Larsson, & Adamson, 2016) . Interestingly, this study found that although people with ASD engaged with treatment as much as non-ASD, the same was found in another adult inpatient sample (Huke, Turk, Saeidi, Kent, & Morgan, 2014) 7 
| S T RE NG TH S A ND L I M IT AT I ONS
A major strength of this study was the use of multimodal and multiinformant assessments measures (DAWBA; SAS; SDQ) and the setting within a RCT with repeated assessment measures (e.g., monthly weight measures). Nevertheless, given the low prevalence of ASD traits, the study may not have had sufficient power to detect different outcomes.
Also, a full cost effectiveness analysis has not been completed.
Although this study was representative of adolescents with AN presenting across the United Kingdom, there may have been a degree of selection, as carers had to agree to participate in order for adolescents to be included in the study. Also, we didn't use a structured clinical interview with patients to diagnose ASD and we didn't control for the presence of other comorbidities. Finally, the use of a six-item assessment (SEED) might have impaired our analysis as it didn't cover all the aspects of ED symptomatology.
| C ONC LUSI ON
For the most part, the eating disorder symptoms in adolescents/young adults with AN and ASD traits resolve in the same time frame, and to the same degree, as those of people with AN without such traits. Continuing problems in social and emotional functioning occurred in those with broad ASD traits and those with an ASD diagnosis.
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